1. Introduction {#sec1}
===============

Human leukocyte antigens (HLAs) are major histocompatibility complex proteins located on the cell surface in humans. Research studies have proved that HLA plays a critical role in recognizing peptide fragments derived from pathogens and exposing them on the cell surface for the activation of specific T cells.^[@ref1],[@ref2]^ Therefore, the identification of peptides bound to HLA is very important for the mechanistic research of cell-mediated immunity and related epitope-based vaccine design. However, the experimental identification of HLA-binding peptides is extremely expensive, laborious, and time-consuming. In this context, in silico prediction of HLA-binding peptides is a cost-effective alternative method.

To date, the methods for predicting HLA-binding peptides can be mainly divided into three categories: (1) scoring matrix-based, (2) structure-based, and (3) machine learning-based. The PSSMHCpan1.0, RANKPEP, and SYFPEITHI are the representative scoring matrix-based methods, which are especially useful when the experimental binding data are limited. The structure-based methods, such as residue-based statistical energy function,^[@ref3]^ can provide important insights into the binding mechanism at the atom level. However, the prediction accuracy remains a challenge because of limited crystallized HLA--peptide complexes and underdeveloped molecular force fields.^[@ref4]−[@ref6]^

In the last two decades, machine learning-based methods, especially artificial neural network (ANN), have been widely applied in predicting HLA-binding peptides and have shown larger data capabilities and reliable accuracies.^[@ref7],[@ref8]^ The available methods generally fall into two types: one is allele-specific and the other is pan-specific. In particular, the pan-specific models have proved be very useful for predicting the binding peptides of a given HLA with limited or even no experimental binding data.^[@ref9],[@ref10]^

NetMHC 4.0^[@ref11]^ is a representative allele-specific model, which uses an ensemble method to generate a feed-forward ANN model and assigns peptide-binding scores based on the majority vote of the ensemble networks. The BLOSUM matrix together with a sparse encoding scheme was employed to encode HLA and peptide sequences. For peptides longer or shorter than 9-mers, deletion or insertion is applied to reconcile or extend the original sequences to a core of 9-mers, which enables the ANN model to deal with the peptides of different lengths.

In contrast to NetMHC 4.0, NetMHCpan 4.0^[@ref12]^ is a pan-specific model, which was trained by using both of the peptides identified by in vitro binding assay and naturally presented peptides by mass spectrometry. The input of NetMHCpan 4.0 consisted of a peptide and a pseudo-sequence of MHC molecule. All the peptides were represented as 9-mer binding cores by using the same method as in NetMHC 4.0.

Taking the advantage of deep learning (DL) technology, Vang and Xie^[@ref13]^ established a allele-specific convolutional neural network (CNN) model to predict HLA-I-binding peptides. In this study, the peptides with the same length (9-mer) were first mapped into a 15-dimensional vector space by using an embedding layer, and the obtained two-dimensional (2-D) arrays were further extracted or filtered by two 1-D convolutional layers. The results showed that the CNN model achieved state-of-the-art area under the receiver operating characteristic curve (AUC) performance in 10 of 15 alleles in the immune epitope database (IEDB) benchmark datasets.

Subsequently, a pan-specific deep CNN (DCNN) model was developed by Han and Kim^[@ref14]^ for predicting HLA-I-binding peptides with the same length (9-mers). In this research, the nonapeptide sequence together with 34 contacting residues of HLA molecule was encoded into a three-dimensional image-like array with the dimension of 34 (width) × 9 (height) × 18 (property channels). Then, the encoded information was processed sequentially by three concatenated convolution blocks with two convolution layers, a max pooling layer, and then three dense layers. The results showed that the DCNN model achieved higher performance than NetMHCpan on 68 test datasets consisting of 43 subsets of HLA-A alleles and 25 subsets of HLA-B alleles.

Recently, Liu et al.^[@ref15]^ proposed a pan-specific CNN model, denoted as DeepSeqPan, to predict not only HLA-binding probabilities but also IC~50~ values of the peptides with 9-mers. In contrast to the DCNN model, the DeepSeqPan was trained simply on raw peptide and HLA sequences encoded by a one-hot scheme. In comparison with the available pan-specific models, the DeepSeqPan model achieved the highest AUC scores in 19 out of 64 IEDB test datasets.

Wu et al.^[@ref16]^ proposed a DeepHLApan model, which adopted bidirectional gated recurrent unit (BiGRU) with a one-hot encoding scheme for predicting both the binding possibilities and potential immunogenicities of the HLA-I-binding peptides simultaneously. In this research, peptides concatenated with HLA pseudo-sequences were used as model inputs. If the length of the combined sequence was shorter than 49 residues, a pseudo-residue "X" would be used for sequence padding. The results showed that the DeepHLApan model achieved comparable performances in predicting the binding peptides with the other well-acknowledged models.

Phloyphisut et al.^[@ref17]^ also developed a pan-specific MHCSeqNet model for predicting MHC-binding peptides. In this paper, the peptide sequences were embedded by a 1-gram model and then processed by a BiGRU layer. The prealigned pseudo-sequences of MHC alleles were auto-embedded and then processed by a fully connected layer or a gated recurrent unit (GRU) layer. The outputs from the peptide and MHC processing layers were concatenated and further processed by two fully connected layers. In this paper, an ensemble model was constructed based on a 5-fold cross-validation scheme, of which the final prediction results were defined as the median of the outputs from the five models established, respectively, on the five data partitions. Although the AUC performances on the 41 MHC alleles are significantly higher than that of NetMHCpan and MHCflurry models, the prediction performances of the MHCSeqNet model need to be further validated by an independent test dataset with precise MHC-restricted-binding profiles.

The pan-specific NetMHCpan 4.0, DeepHLApan, and MHCSeqNet methods can deal with the peptides of different lengths; however, the procedures of sequence reconciliation, padding, or alignment are a bit complex, which limit their application on a large degree. In this paper, a GRU-based DL network was successfully used for establishing a pan-specific prediction model of HLA-I-binding peptides. The GRU-based model used 1-letter coded sequence information of 34 contacting residues of HLA and bound peptides as model inputs without additional sequence processes. Also, the GRU model adopted a simple sequential architecture, which makes it easy for implementation. In comparison with the available six allele-specific, four pan-specific, and two ensemble-based prediction models, the established GRU-based model achieved state-of-the-art performance on 64 entries of the test benchmark datasets.

2. Methods {#sec2}
==========

2.1. Datasets {#sec2.1}
-------------

The compiled dataset of binding_data_2013 from IEDB^[@ref18]^ database (<http://tools.iedb.org/main/datasets>) was used for training and validating the GRU models. After removing 77 peptides with the AA length larger than 15, a total of 156,844 HLA-peptide pairs were obtained, which involved 42 HLA-A alleles with 97,669 binding peptides, 50 HLA-B alleles with 56,731 binding peptides, and 10 HLA-C alleles with 2444 binding peptides ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The information of the 102 HLA-I alleles with the 156,844 binding peptides is shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}. Then, the 156,844 HLA-peptide pairs were randomly divided into training and validation datasets at a ratio of 4:1. Herein, 500 nM threshold was used for converting IC~50~ values of the binding peptides into binary labels. For the samples with the binding affinities determined by *t*~1/2~, 120 min was used as the threshold for label conversion.

![HLA-I alleles and the binding peptides in the binding_data_2013 dataset.](ao0c02039_0001){#fig1}

###### Statistical Information of the Binding_Data_2013 and IEDB's Benchmark Datasets Ranging from 2014-03-21 to 2019-02-01

  dataset            training/validation datasets   test datasets                                                  
  ------------------ ------------------------------ --------------- ------ --------- ------ -------- ------ ------ --------
  no. of alleles     42                             50              10     102       14     14       5      1      33
  no. of peptides    97,669                         56,731          2444   156,844   3515   29,161   541    859    34,076
  no. of negatives   69,511                         45,246          1477   11,6234   2453   9230     459    389    12,531
  no. of positives   28,158                         11,485          967    40,610    1062   19,931   82     470    21,545
  ratio (Neg/Pos)    2.47                           3.94            1.50   2.86      2.31   0.46     6.00   0.83   0.58

The test dataset was retrieved from IEDB's weekly benchmark datasets ranging from 2014-03-21 to 2019-02-01 (<http://tools.iedb.org/auto_bench/mhci/weekly>). After removing duplicate HLA-peptide pairs with the binding_data_2013, 34,076 HLA-peptide pairs were obtained, which involved 14 HLA-A alleles with 4374 binding peptides, 14 HLA-B alleles with 29,161 peptides, and 5 HLA-C alleles with 541 peptides ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The information of the 33 HLA-I alleles and 34,076 binding peptides in total is shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}.

![HLA-I alleles and the binding peptides in the IEDB's weekly benchmark datasets (2014-03 to 2019-02).](ao0c02039_0002){#fig2}

2.2. Encoding of HLA-Peptide Pairs {#sec2.2}
----------------------------------

In this paper, the pseudo-sequences of HLA-I alleles^[@ref10]^ were used for HLA encoding, which consisted of 34 contacting residues. Similar to the encoding of natural language, a given HLA-peptide pair can now be encoded into a 1-letter AA sequence of 34 HLA contacting residues followed by the bound peptide, which was used directly as the input of the GRU network.

2.3. GRU Architecture {#sec2.3}
---------------------

[Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} shows the GRU architecture used in this paper, which consists of one embedding layer, one GRU layer, and five dense layers. Herein, an auto-embedding layer with 128 dimensions was used for indexing the HLA-peptide sequences into multidimensional array data. For a pair of HLA-nanopeptide, for example, it can be transformed into a 2-D tensor with the dimension of 43(=34 + 9) × 128. Followed by an GRU layer with 128 dimensions, five dense layers with ReLU activation function were added sequentially, of which the numbers of neurons were 256, 1024, 1024, 256, and 256, respectively. In the output layer, the softmax activation function was adopted for this binary classification problem. In order to avoid overfitting, dropout^[@ref21]^ and recurrent dropout were used in the GRU layer and spatial dropout in the embedding layer. In addition, early stopping was also implemented if the validation accuracy had not improved within 10 epochs. Because of the imbalance between the number of positive and negative samples, a class weight of 1.93:0.67 (positive/negative) was applied in the training process.

![Architecture of the GRU network.](ao0c02039_0003){#fig3}

2.4. Model Evaluation {#sec2.4}
---------------------

Accuracy, AUC, and *F*~1~ score were used for model evaluations. Herein, the *F*~1~ score is defined as the harmonic mean of precision and recall ([eqs [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}--[3](#eq3){ref-type="disp-formula"}), where it reaches the best value at 1 and worst at 0.where TP, FP, and FN are the numbers of true positives, false positives, and false negatives, respectively.

3. Results and Discussion {#sec3}
=========================

3.1. Performances of the GRU Network by Using Different Loss Functions {#sec3.1}
----------------------------------------------------------------------

The loss function is used to estimate the inconsistency between the predicted and the observed values. Based on the same network architecture, as shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}, four loss functions, that is, sparse categorical cross-entropy, Kullback--Leibler divergence, hinge, and squared hinge were used for GRU modeling, with the Adam optimizer at a learning rate of 0.001. From the modeling results ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), it can be observed that the performances of sparse categorical cross-entropy on both of the training and validation datasets are generally superior to that of other loss functions. Thus, sparse categorical cross-entropy was selected as the optimal loss function.

![Performances of the GRU models on the training (A) and validation datasets (B).](ao0c02039_0004){#fig4}

3.2. Performances of the GRU Network by Using Different Optimizers {#sec3.2}
------------------------------------------------------------------

Herein, five optimizers, that is, Adam, SGD, RMSprop, Adagrad, and Adadelta with default parameters were investigated by using the same network architecture ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). From the modeling results ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}), it can be seen that, in general, the performances of Adam, SGD, and RMSprop are better than that of Adagrad and Adadelta. According to the AUC, *F*~1~, and Mcc values of the validation dataset, RMSprop was selected as the optimal optimizer. In addition, the learning rate of RMSprop was also investigated. The results showed no significant differences in the modeling performances among the learning rates of 0.0001, 0.001, 0.002, and 0.01. Therefore, the learning rate was kept as the default value of 0.001.

![Performances of the GRU network on the training (A) and validation datasets (B) by using different optimizers.](ao0c02039_0005){#fig5}

3.3. Performances of the GRU Model on the Training and Validation Datasets {#sec3.3}
--------------------------------------------------------------------------

Based on the determined loss function and optimizer, the GRU network was trained and validated by the 156,844 HLA-peptide pairs. [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"} shows the evolutions of the loss values and accuracies of the training and validation datasets. It can be observed that the loss values of the training and validation datasets tend to converge at about 21 training epochs, and that after another 10 training epochs, early stopping was triggered because of no further improvement in the prediction accuracy of the validation set. In general, the performance of the GRU model is very good after 31 training epochs, where the prediction accuracies of the training and validation sets are 0.87 and 0.85, respectively.

![Evolutions of the loss values (A) and accuracies (B) of the GRU network.](ao0c02039_0006){#fig6}

[Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} shows the allele-specific performances on the 102 alleles of both the training and validation datasets. It can be observed that the AUC values of 87 alleles (85.3%) are larger than 0.7, and that the Acc values of 66 alleles (64.7%) are larger than 0.8. For the total 102 alleles, the unweighted means of AUC, Acc, and *F*~1~ are 0.81, 0.83, and 0.76, respectively. Also, the unweighted means of Sen and Spe are 0.75 and 0.74, which indicates the balanced performances between the positive and negative samples.

###### Allele-Specific Performances on the Training and Validation Datasets

  allele            sample size   negative   positive   Neg/Pos    AUC        Acc        Spe    Sen    *F*~1~   Mcc
  ----------------- ------------- ---------- ---------- ---------- ---------- ---------- ------ ------ -------- ------
  A\*0101           4790          4104       686        5.98       0.95       0.89       0.89   0.89   0.90     0.66
  A\*0201           12,157        7682       4475       1.72       0.85       0.77       0.78   0.76   0.78     0.54
  A\*0202           4153          2328       1825       1.28       0.93       0.80       0.68   0.95   0.80     0.64
  A\*0203           6301          3900       2401       1.62       0.75       0.69       0.90   0.33   0.65     0.29
  A\*0204           4             4          0          NA         NA         0.75       0.75   NA     NA       NA
  A\*0205           75            25         50         0.50       0.99       0.95       0.84   1.00   0.95     0.88
  A\*0206           5626          3395       2231       1.52       0.70       0.66       0.80   0.45   0.65     0.27
  A\*0207           80            58         22         2.64       0.92       0.79       0.72   0.95   0.80     0.61
  A\*0210           18            18         0          NA         NA         0.94       0.94   NA     NA       NA
  A\*0211           1085          681        404        1.69       0.97       0.91       0.90   0.91   0.91     0.80
  A\*0212           1183          875        308        2.84       0.98       0.87       0.84   0.97   0.88     0.73
  A\*0216           921           740        181        4.09       0.98       0.90       0.88   0.96   0.90     0.74
  A\*0217           346           169        177        0.96       0.82       0.56       0.09   1.00   0.44     0.21
  A\*0219           1246          1012       234        4.33       0.98       0.88       0.86   0.97   0.89     0.98
  A\*0250           135           47         88         0.53       0.98       0.98       0.94   1.00   0.98     0.95
  A\*0301           7356          5236       2120       2.47       0.91       0.83       0.81   0.86   0.83     0.63
  A\*0302           26            13         13         1.00       0.75       0.69       0.85   0.54   0.68     0.40
  A\*0319           30            16         14         1.14       0.76       0.73       0.81   0.64   0.73     0.46
  A\*1101           6397          4253       2144       1.98       0.26       0.56       0.81   0.05   0.50     0.00
  A\*1102           14            4          10         0.40       0.88       0.79       1.00   0.70   0.80     0.63
  A\*2301           2639          2031       608        3.34       0.93       0.87       0.86   0.90   0.88     0.69
  A\*2402           3278          2573       705        3.65       0.93       0.85       0.84   0.91   0.86     0.66
  A\*2403           1381          1049       332        3.16       0.98       0.93       0.92   0.94   0.93     0.82
  A\*2501           960           889        71         12.52      0.99       0.96       0.96   1.00   0.96     0.79
  A\*2601           4533          4024       509        7.91       0.88       0.78       0.78   0.79   0.82     0.40
  A\*2602           643           475        168        2.83       0.97       0.89       0.86   0.96   0.89     0.76
  A\*2603           537           475        62         7.66       0.97       0.92       0.92   0.89   0.92     0.68
  A\*2902           2787          2070       717        2.89       0.83       0.80       0.85   0.67   0.81     0.50
  A\*3001           2923          2150       773        2.78       0.92       0.86       0.88   0.84   0.87     0.67
  A\*3002           2055          1448       607        2.39       0.86       0.78       0.76   0.81   0.79     0.54
  A\*3101           5711          4111       1600       2.57       0.71       0.71       0.83   0.42   0.71     0.26
  A\*3201           1134          724        410        1.77       0.93       0.76       0.65   0.96   0.77     0.60
  A\*3207           88            9          79         0.11       0.85       0.88       0.22   0.95   0.86     0.21
  A\*3215           74            15         59         0.25       0.73       0.85       0.27   1.00   0.81     0.47
  A\*3301           3595          2890       705        4.10       0.72       0.77       0.89   0.32   0.77     0.23
  A\*6601           219           206        13         15.85      0.97       0.94       0.94   0.92   0.95     0.64
  A\*6801           3793          2219       1574       1.41       0.47       0.51       0.59   0.39   0.51     0.00
  A\*6802           5543          4213       1330       3.17       0.89       0.81       0.82   0.79   0.82     0.55
  A\*6823           82            6          76         0.08       0.75       0.90       0.17   0.96   0.89     0.15
  A\*6901           2565          2316       249        9.30       0.94       0.92       0.99   0.69   0.93     0.60
  A\*7401           15            9          6          1.50       0.83       0.73       0.56   1.00   0.73     0.58
  A\*8001           1171          1049       122        8.60       0.97       0.92       0.94   0.80   0.93     0.65
  B\*0702           4640          3318       1322       2.51       0.95       0.87       0.85   0.92   0.87     0.72
  B\*0801           3536          2733       803        3.40       0.93       0.80       0.76   0.93   0.81     0.60
  B\*0802           1020          983        37         26.57      0.99       0.95       0.95   0.89   0.96     0.59
  B\*0803           470           452        18         25.11      0.96       0.97       0.98   0.78   0.98     0.69
  B\*1401           42            26         16         1.63       0.77       0.60       0.46   0.81   0.59     0.28
  B\*1402           341           298        43         6.93       0.93       0.91       0.95   0.65   0.91     0.60
  B\*1501           4446          3082       1364       2.26       0.94       0.82       0.76   0.95   0.82     0.65
  B\*1502           164           40         124        0.32       0.85       0.77       0.08   1.00   0.69     0.24
  B\*1503           699           314        385        0.82       0.94       0.83       0.64   0.98   0.82     0.67
  B\*1509           832           787        45         17.49      0.98       0.95       0.96   0.89   0.96     0.67
  B\*1517           1447          1068       379        2.82       0.96       0.88       0.87   0.92   0.89     0.73
  B\*1542           364           361        3          120.33     0.95       0.99       1.00   0.00   0.99     0.00
  B\*1801           2830          2752       78         35.28      0.94       0.83       0.83   0.92   0.89     0.31
  B\*2701           4             3          1          3.00       1.00       0.75       1.00   0.00   0.64     0.00
  B\*2702           8             8          0          NA         NA         0.63       0.63   NA     NA       NA
  B\*2703           876           876        0          NA         NA         1.00       1.00   NA     NA       NA
  B\*2704           6             6          0          NA         NA         0.67       0.67   NA     NA       NA
  B\*2705           3674          3009       665        4.52       0.96       0.92       0.95   0.80   0.92     0.74
  B\*2706           7             7          0          NA         NA         0.86       0.86   NA     NA       NA
  B\*2710           2             2          0          NA         NA         1.00       1.00   NA     NA       NA
  B\*2720           92            2          90         0.02       0.87       0.97       0.00   0.99   0.96     0.00
  B\*3501           3209          2237       972        2.30       0.93       0.76       0.67   0.97   0.77     0.60
  B\*3503           282           263        19         13.84      0.95       0.78       0.76   1.00   0.83     0.42
  B\*3508           1             0          1          0.00       NA         1.00       NA     1.00   NA       NA
  B\*3701           68            59         9          6.56       0.68       0.84       0.92   0.33   0.83     0.68
  B\*3801           517           360        157        2.29       0.99       0.92       0.90   0.97   0.92     0.84
  B\*3901           1790          1487       303        4.91       0.96       0.91       0.91   0.90   0.91     0.72
  B\*4001           3441          2809       632        4.44       0.61       0.61       0.62   0.56   0.65     0.14
  B\*4002           1072          738        334        2.21       0.94       0.79       0.71   0.97   0.80     0.62
  B\*4013           59            6          53         0.11       0.61       0.90       0.00   1.00   0.85     0.00
  B\*4201           235           170        65         2.62       0.93       0.88       0.90   0.81   0.88     0.70
  B\*4202           18            4          14         0.29       0.59       0.72       0.00   0.93   0.65     0.00
  B\*4402           2316          1881       435        4.33       0.96       0.87       0.85   0.95   0.88     0.68
  B\*4403           1402          989        413        2.39       0.95       0.82       0.76   0.96   0.82     0.66
  B\*4501           1077          887        190        4.67       0.95       0.89       0.90   0.84   0.90     0.67
  B\*4506           362           358        4          89.50      0.92       0.99       1.00   0.25   0.99     0.50
  B\*4601           1812          1716       96         17.88      0.98       0.96       0.98   0.76   0.97     0.68
  B\*4801           883           810        73         11.10      0.98       0.95       0.96   0.78   0.95     0.69
  B\*5101           2899          2603       296        8.80       0.86       0.90       0.97   0.29   0.88     0.32
  B\*5201           15            12         3          4.00       0.78       0.73       0.75   0.67   0.75     0.35
  B\*5301           1718          1222       496        2.46       0.93       0.72       0.62   0.97   0.74     0.54
  B\*5401           1201          986        215        4.59       0.95       0.91       0.92   0.82   0.91     0.70
  B\*5701           2901          2433       468        5.20       0.97       0.92       0.92   0.91   0.92     0.74
  B\*5702           18            4          14         0.29       0.95       0.89       0.50   1.00   0.89     0.66
  B\*5703           34            7          27         0.21       1.00       0.97       1.00   0.96   0.97     0.92
  B\*5801           3348          2604       744        3.50       0.97       0.89       0.88   0.90   0.89     0.71
  B\*5802           66            53         13         4.08       0.79       0.68       0.64   0.85   0.71     0.40
  B\*7301           122           105        17         6.18       0.85       0.87       0.92   0.53   0.87     0.45
  B\*8101           26            13         13         1.00       0.95       0.65       0.31   1.00   0.61     0.43
  B\*8301           339           299        40         7.48       0.97       0.93       0.94   0.80   0.93     0.68
  C\*0303           154           38         116        0.33       0.89       0.82       0.26   1.00   0.77     0.46
  C\*0401           552           531        21         25.29      0.92       0.97       1.00   0.33   0.97     0.50
  C\*0501           173           105        68         1.54       0.93       0.88       0.92   0.82   0.88     0.76
  C\*0602           409           310        99         3.13       0.95       0.87       0.87   0.87   0.87     0.68
  C\*0701           242           153        89         1.72       0.90       0.79       0.69   0.94   0.79     0.62
  C\*0702           143           59         84         0.70       0.90       0.79       0.63   0.90   0.78     0.56
  C\*0802           87            55         32         1.72       0.79       0.64       0.47   0.94   0.64     0.42
  C\*1203           172           17         155        0.12       0.56       0.91       0.12   1.00   0.88     0.33
  C\*1402           259           72         187        0.39       0.81       0.78       0.19   1.00   0.72     0.39
  C\*1502           253           137        116        1.18       0.84       0.68       0.43   0.97   0.66     0.46
  **mean values**   **0.81**      **0.83**   **0.74**   **0.75**   **0.76**   **0.49**                          

For the peptides with different lengths, the GRU model also exhibited good performances. Taken as the peptides bound to HLA-A\*0201 and HLA-B\*5401, for example ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}), it can be seen that the Acc values of the 8, 10, and 11-mer peptides of each allele are generally satisfactory, although the sample sizes of which are smaller than that of 9-mer peptides.

![Prediction performances on the HLA-A\*0201 and HLA-B\*5401.](ao0c02039_0007){#fig7}

In addition, the same GRU architecture was also used to establish the prediction models of HLA-A, -B, and -C subtypes ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}). For each of the three models, it can be observed that the Acc and Sen values of both the training and validation datasets are larger than 0.80, and that the AUC values are larger than 0.90. Therefore, it can be inferred that the GRU architecture adopted in this paper can be applied flexibly to predict the binding peptides of a specific HLA-I subtype.

![Training (A) and validation (B) performances of the GRU models for HLA-A, -B, and -C subtypes.](ao0c02039_0008){#fig8}

3.4. Prediction Performances of the GRU Model on the Independent Test Datasets {#sec3.4}
------------------------------------------------------------------------------

[Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} shows the AUC performances of the GRU model on the independent test datasets. The test datasets were derived from the IEDB weekly benchmark datasets ranging from 2014-03 to 2019-02, which include 33 HLA-I alleles with 34,075 binding peptides (8--11-mers). From [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, it can be observed that the GRU model exhibits satisfactory AUC performances on the 68 entries of the test datasets.

###### AUC Performances on the Test IEDB's Weekly Benchmark Datasets (2014-03 to 2019-02)[a](#t3fn1){ref-type="table-fn"}

![](ao0c02039_0009){#gr9}

The highest AUCs are highlighted in yellow, and the AUCs differ by less than 0.1 from the highest are in cyan.

For the purpose of comparison, [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} also shows the AUC performances of the GRU model on the 9-mer peptides of the IEDB benchmark datasets ranging from 2014-03 to 2018-01, together with that of the pan-specific DeepSeqPan,^[@ref15]^ NetMHCpan (2.8),^[@ref9]^ NetMHCpan (3.0),^[@ref22]^ and PickPocket,^[@ref23]^ allele-specific SMM,^[@ref24]^ NetMHC (3.4),^[@ref25]^ NetMHC (4.0),^[@ref11]^ ARB,^[@ref26]^ MHCfurry,^[@ref20]^ and AMMPMBEC,^[@ref26]^ and ensemble-based IEDB consensus^[@ref26]^ and NetMHCcons^[@ref27]^ models. It can be observed that the GRU model achieves the highest AUC scores for 21 from 64 entries. Besides, the GRU model also achieves satisfactory AUC scores for 24 other entries, of which the AUC scores differ by less than 0.1 from the highest scores. Overall, the number of entries with the highest AUC scores of the GRU model is a little lower than that of the NetMHCpan (2.8) model and higher than that of 11 other models. Herein, it should be noted that, in comparison with the NetMHCpan model, the GRU model can predict the peptides with varying lengths by a simple and direct manner without sequence reconciliation.

Taken as the HLA-A\*0201, B\*0702, B\*2705, and B\*3501 alleles, for example, [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"} shows the AUC performances on the test peptides with different lengths. It can be observed that the AUC scores for 8-mer, 10-mer, and 11-mer peptides of each allele are satisfactory, except for the 8-mer peptides of B\*2705 allele. It is worth noting that the AUC scores of the main source entry (IEDB REF: 1031959) of the B\*2705 binding peptides are relatively lower among all of the prediction models ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). Besides, the sample size of the peptides except for nonapeptides is relatively small, and the true predictive power of the GRU model for peptides with different lengths needs to be further tested.

###### AUC Performances on the Peptides with Different Lengths

  length             9-mers    10-mers   11-mers   8-mers    9-mers   10-mers   11-mers   8-mers   9-mers   10-mers   11-mers   8-mers   9-mers   10-mers   11-mers
  ------------------ --------- --------- --------- --------- -------- --------- --------- -------- -------- --------- --------- -------- -------- --------- ---------
  allele             A\*0201   B\*0702   B\*2705   B\*3501                                                                                                  
  total number       784       48        35        12        234      20        15        97       13,573   7663      5330      10       419      15        17
  no. of negatives   483       22        17        8         147      8         5         68       4188     2068      1335      6        276      10        13
  no. of positives   301       26        18        4         87       12        10        29       9385     5595      3995      4        143      5         4
  AUC                0.73      0.70      0.76      0.84      0.81     0.82      0.82      0.47     0.63     0.55      0.66      0.58     0.75     0.72      0.52

4. Conclusions {#sec4}
==============

In this work, we proposed a simple GRU-based recurrent neural network model for the pan-specific prediction of HLA-I-binding peptides. Extensive evaluation and comparison analysis showed that the GRU model exhibits state-of-the-art performances on the public available IEDB benchmark datasets. The key features of the GRU model can be summarized as the following three points. The first point is that the GRU model can, because of its pan-specific property, be used to predict the binding peptides for all the HLA-I alleles even without any experimental binding data. Second, the GRU model uses only the sequence information of the HLA and peptide as inputs and can predict the peptides with varying lengths in a simple and direct manner. Last, the GRU model adopts a simple sequential network architecture, which makes it easy for implementation. Overall, the pan-specific GRU model proposed in this paper has strong predictive power and distinctive features. In addition, the successful experiences in the HLA-I-binding peptides would be beneficial for predicting HLA-II-binding peptides.
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